

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|--|
| (51) International Patent Classification ⁷ : C12Q 1/68, C07K 1/00, 17/00, C07H 21/00 | A1 | (11) International Publication Number: WO 00/47774 (43) International Publication Date: 17 August 2000 (17.08.00) |
| (21) International Application Number: PCT/US00/02490 (22) International Filing Date: 1 February 2000 (01.02.00) (30) Priority Data: 09/246,461 9 February 1999 (09.02.99) US (71) Applicant: NEXSTAR PHARMACEUTICALS, INC. [US/US]; Suite 200, 2860 Wilderness Place, Boulder, CO 80301 (US). (72) Inventors: JANJIC, Nebojsa; 6973 Carter Trail, Boulder, CO 80301 (US). GOLD, Larry; 1033 5th Street, Boulder, CO 80302 (US). (74) Agents: SWANSON, Barry, J. et al.; Swanson & Bratschun, L.L.C., 1745 Shea Center Drive, Suite 330, Highlands Ranch, CO 80126 (US). | | (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: APTAMERS AS REAGENTS FOR HIGH THROUGHPUT SCREENING | | |
| (57) Abstract The invention relates to the use of aptamers in high throughput screening methods to determine whether a non-nucleic acid molecule, i.e. small molecule, binds to a target. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

APTAMERS AS REAGENTS FOR HIGH THROUGHPUT SCREENING

FIELD OF THE INVENTION

5 This invention is directed to a high throughput screening (HTS) method that uses aptamers to facilitate the identification of non-aptamer ligands, typically small molecules. Aptamers can be identified that bind to a wide variety of targets and can be used to identify small molecules that can compete with the aptamers for binding to the target.

10 BACKGROUND OF THE INVENTION

 Drug discovery in most pharmaceutical companies is heavily focused on the identification of orally active compounds. High throughput screening (HTS) of appropriate libraries of compounds (generally small molecules) against validated targets constitutes one of the major activities in discovery research groups whose overall goal is to
15 create and/or maintain a pipeline of new drug candidates. The development of HTS assays that allow efficient detection of active compounds from such libraries is thus a critically important component of drug discovery. With increasing numbers of both validated targets and compound libraries, HTS laboratories are under considerable pressure to find ways to increase throughput and lower cost. Assay development and validation is often
20 one of the bottlenecks in this process (Fox *et al.* (November 1998) Drug Discovery & Development (Supplement to R&D Magazine) pp. 32-37, incorporated by reference in its entirety).

 Aptamers (also termed nucleic acid ligands) are structurally unique nucleic acids capable of binding other molecules (i.e., targets) with high affinity and specificity.
25 Aptamers are derived from large random libraries by the SELEX process in which iterative rounds of affinity selection and amplification are used to identify sequences with specific binding properties. The SELEX process is described in more detail below. To date, aptamers that bind to small organic molecules, carbohydrates, amino acids, peptides and proteins have been identified, illustrating the multitude of binding specificities present in
30 large collections of single stranded nucleic acid sequences (Gold *et al.* (1995) Annu. Rev. Biochem. 64:763-797). Aptamers bind to protein targets including growth factors, enzymes, receptors and structural proteins in a highly specific manner and with dissociation constants typically in the nanomolar (and sometimes picomolar) range. Given these unique binding properties, nuclease stabilized and appropriately formulated aptamers

have substantial potential as therapeutics. For therapeutic uses, aptamers, like antibodies, are delivered parenterally because of their limited oral availability.

The dogma for many years was that nucleic acids had primarily an informational role. Through a method known as Systematic Evolution of Ligands by EXponential enrichment, termed the SELEX process, it has become clear that nucleic acids have three dimensional structural diversity not unlike proteins. The SELEX process is a method for the *in vitro* evolution of nucleic acid molecules with highly specific binding to target molecules and is described in United States Patent Application Serial No. 07/536,428, filed June 11, 1990, entitled "Systematic Evolution of Ligands by EXponential Enrichment," now abandoned, United States Patent Application Serial No. 07/714,131, filed June 10, 1991, entitled "Nucleic Acid Ligands," now United States Patent No. 5,475,096, and United States Patent Application Serial No. 07/931,473, filed August 17, 1992, entitled "Methods for Identifying Nucleic Acid Ligands," now United States Patent No. 5,270,163 (see also WO 91/19813), each of which is specifically incorporated by reference herein. Each of these applications, collectively referred to herein as the SELEX Patent Applications, describes a fundamentally novel method for making a nucleic acid ligand to any desired target molecule. The SELEX process provides a class of products which are referred to as aptamers or nucleic acid ligands, each ligand having a unique sequence, and which has the property of binding specifically to a desired target compound or molecule. Each SELEX-identified nucleic acid ligand is a specific ligand of a given target compound or molecule. The SELEX process is based on the unique insight that nucleic acids have sufficient capacity for forming a variety of two- and three-dimensional structures and sufficient chemical versatility available within their monomers to act as ligands (form specific binding pairs) with virtually any chemical compound, whether monomeric or polymeric. Molecules of any size or composition can serve as targets.

The SELEX method applied to the application of high affinity binding involves selection from a mixture of candidate oligonucleotides and step-wise iterations of binding, partitioning and amplification, using the same general selection scheme, to achieve virtually any desired criterion of binding affinity and selectivity. Starting from a mixture of nucleic acids, preferably comprising a segment of randomized sequence, the SELEX method includes steps of contacting the mixture with the target under conditions favorable for binding, partitioning unbound nucleic acids from those nucleic acids which have bound

specifically to target molecules, dissociating the nucleic acid-target complexes, amplifying the nucleic acids dissociated from the nucleic acid-target complexes to yield a ligand-enriched mixture of nucleic acids, then reiterating the steps of binding, partitioning, dissociating and amplifying through as many cycles as desired to yield highly specific
5 high affinity nucleic acid ligands to the target molecule.

The SELEX method demonstrates that nucleic acids as chemical compounds can form a wide array of shapes, sizes and configurations, and are capable of a far broader repertoire of binding and other functions than those displayed by nucleic acids in biological systems. SELEX or SELEX-like processes can be used to identify nucleic acids
10 which can facilitate any chosen reaction in a manner similar to that in which nucleic acid ligands can be identified for any given target. In theory, within a candidate mixture of approximately 10^{13} to 10^{18} nucleic acids, at least one nucleic acid exists with the appropriate shape to facilitate each of a broad variety of physical and chemical interactions.

15 The basic SELEX method has been modified to achieve a number of specific objectives. For example, United States Patent Application Serial No. 07/960,093, filed October 14, 1992, entitled "Method for Selecting Nucleic Acids on the Basis of Structure," now abandoned (see United States Patent No. 5,707,796) describes the use of the SELEX process in conjunction with gel electrophoresis to select nucleic acid molecules with
20 specific structural characteristics, such as bent DNA. United States Patent Application Serial No. 08/123,935, filed September 17, 1993, entitled "Photoselection of Nucleic Acid Ligands," now abandoned (see United States Patent No. 5,763,177) describes a SELEX based method for selecting nucleic acid ligands containing photoreactive groups capable of binding and/or photocrosslinking to and/or photoinactivating a target molecule. United
25 States Patent Application Serial No. 08/134,028, filed October 7, 1993, entitled "High-Affinity Nucleic Acid Ligands That Discriminate Between Theophylline and Caffeine," now abandoned (see United States Patent No. 5,580,737), describes a method for identifying highly specific nucleic acid ligands able to discriminate between closely related molecules, which can be non-peptidic, termed Counter-SELEX. United States
30 Patent Application Serial No. 08/143,564, filed October 25, 1993, entitled "Systematic Evolution of Ligands by EXponential Enrichment: Solution SELEX," now abandoned (see United States Patent No. 5,567,588), describes a SELEX-based method which

achieves highly efficient partitioning between oligonucleotides having high and low affinity for a target molecule.

The SELEX method encompasses the identification of high-affinity nucleic acid ligands containing modified nucleotides conferring improved characteristics on the ligand, such as improved in vivo stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions. SELEX process-identified nucleic acid ligands containing modified nucleotides are described in United States Patent Application Serial No. 08/117,991, filed September 8, 1993, entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides," now abandoned (see United States Patent No. 5,660,985), that describes oligonucleotides containing nucleotide derivatives chemically modified at the 5- and 2'-positions of pyrimidines. United States Patent Application Serial No. 08/134,028, supra, describes highly specific nucleic acid ligands containing one or more nucleotides modified with 2'-amino (2'-NH₂), 2'-fluoro (2'-F), and/or 2'-O-methyl (2'-OMe). United States Patent Application Serial No. 08/264,029, filed June 22, 1994, entitled "Novel Method of Preparation of Known and Novel 2' Modified Nucleosides by Nucleophilic Displacement," describes oligonucleotides containing various 2'-modified pyrimidines.

The SELEX method encompasses combining selected oligonucleotides with other selected oligonucleotides and non-oligonucleotide functional units as described in United States Patent Application Serial No. 08/284,063, filed August 2, 1994, entitled "Systematic Evolution of Ligands by EXponential Enrichment: Chimeric SELEX," now United States Patent No. 5,637,459, and United States Patent Application Serial No. 08/234,997, filed April 28, 1994, entitled "Systematic Evolution of Ligands by EXponential Enrichment: Blended SELEX," now United States Patent No. 5,683,867, respectively. These applications allow the combination of the broad array of shapes and other properties, and the efficient amplification and replication properties, of oligonucleotides with the desirable properties of other molecules.

The SELEX method further encompasses combining selected nucleic acid ligands with lipophilic compounds or non-immunogenic, high molecular weight compounds in a diagnostic or therapeutic complex as described in United States Patent Application Serial No. 08/434,465, filed May 4, 1995, entitled "Nucleic Acid Ligand Complexes." Each of

the above described patent applications which describe modifications of the basic SELEX procedure are specifically incorporated by reference herein in their entirety.

SUMMARY OF THE INVENTION

5 The present invention describes the use of aptamers to facilitate the identification of non-aptamer ligands. More specifically, the present invention includes the use of aptamers in competition binding assays to rapidly identify compounds that are capable of displacing the aptamers from their targets. The affinities of competitor compounds can be calculated from the known affinity of the aptamer for its target and the competition
10 profiles. The method is highly versatile and compatible with a variety of HTS platforms since aptamers, as chemically synthesized molecules, can be labeled in a variety of ways without compromising their binding affinity.

 The method of the invention is illustrated with two protein targets: platelet derived growth factor (PDGF) and wheat germ agglutinin (WGA). For each protein, a small
15 biased set of molecules is screened for their ability to displace the cognate aptamer: naphthalene sulfonic acid derivatives for PDGF and oligosaccharides for WGA. For both PDGF and WGA, best ligands can be identified readily. Furthermore, binding affinities of the competitors correlate with their activities in *in vitro* assays (*infra*, and in United States Patent Number 5,780,222, issued July 14, 1998).

20

BRIEF DESCRIPTION OF THE FIGURES

 Figure 1 depicts the structures of small molecule oligoanion competitors used in the PDGF competition assay (dashed lines (c_{2v}) indicate a 2-fold axis of symmetry) along with the K_{dc} values calculated from the competition profiles according to equations (1)-(3)
25 and EC50 values derived from ^3T -thymidine uptake assays.

 Figures 2A, 2B and 2C depict the competition profiles of the various small molecule oligoanion competitors for displacing the binding of a PDGF aptamer to PDGF.

 Figure 3 depicts the structures of small molecule oligosaccharide competitors used in the WGA competition assay along with the K_{dc} values calculated from the competition
30 profiles according to equations (1)-(3).

Figures 4A, 4B, 4C and 4D depict the competition profiles of the various small molecule oligosaccharide competitors for displacing the binding of the WGA aptamer to WGA.

5 DETAILED DESCRIPTION OF THE INVENTION

The present invention describes the use of aptamers as a new class of reagents for high throughput screening (HTS) that may be used in conjunction with or in place of cell-based assays, receptor binding and other protein-protein interaction assays. The identification of aptamers to protein targets generally requires 5-15 rounds of the SELEX process to achieve affinities in the nanomolar range. A round of the SELEX process using manual protocols takes about one day, and considerably less than that using automated protocols such as those described in United States Patent Application Serial No. 09/232,946, entitled "Method and Apparatus for the Automated Generation of Nucleic Acid Ligands," filed January 19, 1999, which is incorporated herein in its entirety.

15 Aptamer identification is thus rapid.

It is important to note that for use in competition assays described here, the affinity of aptamers for their targets need not be very high, since the affinity of first generation lead compounds will typically be considerably lower than that of an aptamer (e.g., in the micromolar range). For example, for the purposes of this invention it was useful to reduce the affinity of a previously identified PDGF aptamer (described in United States Patent No. 5,723,594, entitled "High Affinity PDGF Nucleic Acid Ligands," issued March 3, 1998, which is incorporated herein in its entirety) about 10-fold to facilitate the identification of competitors that bind PDGF with micromolar affinities. Lower affinity requirements may further speed up the identification of appropriate aptamers for competition assays. More generally, the affinities of aptamers and binding conditions (such as concentrations of the binding species) can be tuned to facilitate detection of ligands in a defined concentration range. Aptamers may be particularly useful for the identification of ligands to protein targets that do not have a known binding partner, such as orphan receptors.

30 The use of competition binding screens with aptamers (or any other ligands) does not guarantee that all compounds from a library that are capable of binding to the target will be identified, since the assay requires competitive displacement. To decrease the

chance that active compounds may be missed, one can use more than one aptamer for the screens. It is important to note in this context, however, that in most cases, aptamers identified to protein targets generally compete with each other even when they belong to different sequence families or have different compositions (RNA, DNA or modified RNA). Nevertheless, given their size (typically 6-13 kDa), most aptamers are likely to cover a significant surface fraction of their protein targets which should reduce the problem of false negatives in competition assays. Furthermore, as illustrated with the WGA aptamers (described in United States Patent Number 5,780,228, entitled "High Affinity Nucleic Acid Ligands to Lectins," issued July 14, 1998, which is incorporated herein in its entirety), aptamers that bind to specific sites on proteins can be selected provided that a ligand that binds to that site is available.

High affinity binding of aptamers for protein targets is typically encoded in sequences of 20-40 nucleotides. The efficient encoding of high affinity binding allows aptamers to be synthesized entirely chemically, e.g. by the solid phase phosphoramidite method. Aside from the advantage of being able to control batch-to-batch variability and lower reagent cost, chemical synthesis facilitates the incorporation of various non-nucleic acid functionalities into aptamers in a manner that does not disrupt their exquisite binding properties. Therefore, although radiolabeled aptamers are used in the examples herein, aptamers can be labeled in a variety of other ways (e.g., with light-absorbing, fluorescent or chemiluminescent moieties, biotin, etc.) that may be more suitable for some HTS applications.

Definitions

Various terms are used herein to refer to aspects of the present invention. To aid in the clarification of the description of the components of this invention, the following definitions are provided.

As used herein, "aptamer" or "nucleic acid ligand" is a non-naturally occurring nucleic acid having a desirable action on a target. A desirable action includes, but is not limited to, binding of the target, catalytically changing the target, reacting with the target in a way which modifies/alters the target or the functional activity of the target, covalently attaching to the target as in a suicide inhibitor, facilitating the reaction between the target and another molecule. In the preferred embodiment, the action is specific binding affinity

for a target molecule, such target molecule being a three dimensional chemical structure other than a polynucleotide that binds to the nucleic acid ligand through a mechanism which predominantly depends on Watson/Crick base pairing or triple helix binding, wherein the nucleic acid ligand is not a nucleic acid having the known physiological function of being bound by the target molecule. Nucleic acid ligands include nucleic acids that are identified from a candidate mixture of nucleic acids, said nucleic acid ligand being a ligand of a given target, by the method comprising: a) contacting the candidate mixture with the target, wherein nucleic acids having an increased affinity to the target relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and c) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids.

As used herein, "non-aptamer ligands" or "non-nucleic acid molecule" is any molecule that is not an aptamer. Typically this term includes but is not limited to small molecules.

As used herein, "candidate mixture" is a mixture of nucleic acids of differing sequence from which to select a desired aptamer. The source of a candidate mixture can be from naturally-occurring nucleic acids or fragments thereof, chemically synthesized nucleic acids, enzymatically synthesized nucleic acids or nucleic acids made by a combination of the foregoing techniques. In a preferred embodiment, each nucleic acid has fixed sequences surrounding a randomized region to facilitate the amplification process.

As used herein, "nucleic acid" means either DNA, RNA, single-stranded or double-stranded, and any chemical modifications thereof. Modifications include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole. Such modifications include, but are not limited to, 2'-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil; backbone modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and

isoguanidine and the like. Modifications can also include 3' and 5' modifications such as capping.

"SELEX" methodology involves the combination of selection of nucleic acid ligands which interact with a target in a desirable manner, for example binding to a protein, with amplification of those selected nucleic acids. Optional iterative cycling of the selection/amplification steps allows selection of one or a small number of nucleic acids which interact most strongly with the target from a pool which contains a very large number of nucleic acids. Cycling of the selection/amplification procedure is continued until a selected goal is achieved. The SELEX methodology is described in the SELEX Patent Applications.

"Target" means any compound or molecule of interest for which a ligand is desired. A target can be a protein, peptide, carbohydrate, polysaccharide, glycoprotein, hormone, receptor, antigen, antibody, virus, substrate, metabolite, transition state analog, cofactor, inhibitor, drug, dye, nutrient, growth factor, etc. without limitation.

As used herein, "solid support" is defined as any surface to which molecules may be attached through either covalent or non-covalent bonds. This includes, but is not limited to, membranes, plastics, magnetic beads, charged paper, nylon, Langmuir-Bodgett films, functionalized glass, germanium, silicon, PTFE, polystyrene, gallium arsenide, gold and silver. Any other material known in the art that is capable of having functional groups such as amino, carboxyl, thiol or hydroxyl incorporated on its surface, is also contemplated. This includes surfaces with any topology, including, but not limited to, spherical surfaces and grooved surfaces.

"Partitioning" means any process whereby aptamers bound to target molecules can be separated from nucleic acids not bound to target molecules. More broadly stated, partitioning allows for the separation of all the nucleic acids in a candidate mixture into at least two pools based on their relative affinity to the target molecule. Partitioning can be accomplished by various methods known in the art. Nucleic acid-protein pairs can be bound to nitrocellulose filters while unbound nucleic acids are not. Columns which specifically retain nucleic acid-target complexes can be used for partitioning. For example, oligonucleotides able to associate with a target molecule bound on a column allow use of column chromatography for separating and isolating the highest affinity nucleic acid ligands. Beads upon which target molecules are conjugated can also be used

to partition nucleic acid ligands in a mixture. Surface plasmon resonance technology can be used to partition nucleic acids in a mixture by immobilizing a target on a sensor chip and flowing the mixture over the chip, wherein those nucleic acids having affinity for the target can be bound to the target, and the remaining nucleic acids can be washed away.

- 5 Liquid-liquid partitioning can be used as well as filtration gel retardation, and density gradient centrifugation.

In its most basic form, the SELEX process may be defined by the following series of steps:

- 1) A candidate mixture of nucleic acids of differing sequence is prepared. The
10 candidate mixture generally includes regions of fixed sequences (i.e., each of the members of the candidate mixture contains the same sequences in the same location) and regions of randomized sequences. The fixed sequence regions are selected either: a) to assist in the amplification steps described below; b) to mimic a sequence known to bind to the target; or c) to enhance the concentration of a given structural arrangement of the nucleic acids in
15 the candidate mixture. The randomized sequences can be totally randomized (i.e., the probability of finding a base at any position being one in four) or only partially randomized (e.g., the probability of finding a base at any location can be selected at any level between 0 and 100 percent).

- 2) The candidate mixture is contacted with the selected target under conditions
20 favorable for binding between the target and members of the candidate mixture. Under these circumstances, the interaction between the target and the nucleic acids of the candidate mixture can be considered as forming nucleic acid-target pairs between the target and those nucleic acids having the strongest affinity for the target.

- 3) The nucleic acids with the highest affinity for the target are partitioned
25 from those nucleic acids with lesser affinity to the target. Because only an extremely small number of sequences (and possibly only one molecule of nucleic acid) corresponding to the highest affinity nucleic acids exist in the candidate mixture, it is generally desirable to set the partitioning criteria so that a certain amount of the nucleic acids in the candidate mixture are retained during partitioning.

- 30 4) Those nucleic acids selected during partitioning as having relatively higher affinity to the target are then amplified to create a new candidate mixture that is enriched in nucleic acids having a relatively higher affinity for the target.

5) By repeating the partitioning and amplifying steps above, the newly formed candidate mixture contains fewer and fewer unique sequences, and the average degree of affinity of the nucleic acids to the target will generally increase. Taken to its extreme, the SELEX process will yield a candidate mixture containing one or a small number of unique nucleic acids representing those nucleic acids from the original candidate mixture having the highest affinity to the target molecule.

The SELEX Patent Applications describe and elaborate on this process in great detail. Included are targets that can be used in the process; methods for the preparation of the initial candidate mixture; methods for partitioning nucleic acids within a candidate mixture; and methods for amplifying partitioned nucleic acids to generate enriched candidate mixtures. The SELEX Patent Applications also describe ligand solutions obtained to a number of target species, including protein targets wherein the protein is or is not a nucleic acid binding protein.

In the preferred embodiment of this invention, aptamers are used in conjunction with an existing HTS platform that allows inspection of multiple wells in an automated format. Any and all HTS platforms are contemplated for use in the present invention. For example, a target could be immobilized on a solid support and incubated with labeled aptamer. Any labeling method is contemplated by the present invention, including but not limited to radioactive, light-absorbing, fluorescent, chemiluminescent or other detectable moieties. A library of non-aptamer candidate molecules could then be tested for their ability to displace the aptamer from its target by measuring either the amount of labeled aptamer displaced or the amount of labeled aptamer remaining on the solid support. Alternatively, the aptamer could be immobilized on a solid support and incubated with a labeled target. A library of non-aptamer candidate molecules could then be tested for their ability to displace the labeled target as described above. Any known method for detecting the displaced aptamer is contemplated by the present invention, including but limited to direct detection or amplified detection such as that described in United States Application Serial No. 09/157,206 filed September 18, 1998, entitled "Homogenous Detection of a Target Through Nucleic Acid Ligand-Ligand Beacon Interaction," which is incorporated herein in its entirety by reference.

In certain embodiments, the method can take place in solution with the aptamer and small molecule competing simultaneously.

EXAMPLES

The Examples provided below are illustrative embodiments of the invention. They are not to be taken as limiting the scope of the invention.

5

Example 1. Material and Methods

Materials

10 Human recombinant platelet derived growth factor, BB isoform (PDGF BB) was purchased from R&D Systems (Minneapolis, MN) as a carrier free lyophilized powder. Wheat Germ (*Triticum vulgare*) Agglutinin (WGA) was from EY laboratories (San Mateo, CA).

Oligonucleotides were synthesized using an Applied Biosystems Model 394
15 oligonucleotide synthesizer according to optimized protocols. PDGF aptamer 20ta is a synthetic 33-mer DNA oligo of sequence: 5'-CGGGCGCGTTCTTCGTGGTTACTTTT AGTCCCG (SEQ ID NO: 1), aptamer 20tb is a synthetic 27-mer DNA oligo of sequence: 5'-GGGCCGTTTCGGGTTACTTTTAGTCCC (SEQ ID NO: 2), and aptamer PD316 is a synthetic oligo containing some modified (2'-F and 2'-O-methyl, italic and bold letters,
20 respectively) bases, and an 18-atom PEG spacer replacing some bases, to increase serum stability, of sequence: 5'-T_{NH2}CAGGCUACG[PEG₁₈]CGTAGAGCAUCA[PEG₁₈]TGAT CCUG-3'3'T (SEQ ID NO: 3). WGA aptamer 11.20 is a 98-mer RNA transcript with 2'-aminopyrimidine bases of sequence: 5'-GGGAAAAGCGAAUCAUACACAAGAUUG GUCGUACUGGACAGAGCCGUGGUAGAGGGAUUGGGACAAAGUGUCAGCUCC
25 GCCAGAGACCAACCGAGAA (SEQ ID NO: 4). PDGF aptamers were previously described in United States Patent No. 5,723,594, entitled "High Affinity PDGF Nucleic Acid Ligands," issued March 3, 1998. WGA aptamers were previously described in United States Patent No. 5,780,228, entitled "High Affinity Nucleic Acid Ligands to Lectins," issued July 14, 1998.

30 Oligoanions used in the PDGF aptamer competition assay were: Evans blue, trypan Blue, amaranth, sulfonazo III, New Coccine, *myo*inositol hexasulfate, SPADNS (2-(4-sulfophenylazo)-1,8-dihydroxy-3,6-naphthalene disulfonic acid), calcion and azocarmine B from Aldrich (Milwaukee, WI); NTSA (naphthalene 1,3,6-trisulfonic acid)

from Fluka, suramin from Calbiochem (La Jolla, CA) and sucrose octasulfate from Toronto Research Chemicals (Toronto, Canada).

Oligosaccharides used in the WGA aptamer competition assay were: N-acetyl-D-glucosamine (GlcNAc) from Sigma (St. Louis, MO); N,N'-diacetylchitobiose (GlcNAc)₂,
5 N,N',N''-triacetylchitotriose (GlcNAc)₃, N,N',N'',N'''-tetraacetyltetraose (GlcNAc)₄,
galactose 1-β-3(fucose-α-4)glucosamine (Lewis A trisaccharide), galactose 1-β-4(fucose
1-α-3)glucosamine (Lewis X trisaccharide), fucose1-α-2 galactose1-β-4(fucose 1-α-
3)glucosamine (Lewis Y tetrasaccharide), Sialyl Lewis A, Sialyl Lewis X, fucose1-α-
4glucosamine, fucose1-α-3glucosamine, N-acetyl-lactosamine (LacNAc), 3'α-Sialyl-N-
10 acetyllactosamine (α-Sialyl-LacNAc), 3'β-Sialyl-N-acetyllactosamine (β-Sialyl-LacNAc),
from Toronto Research Chemicals (Toronto, Canada).

Methods

Small molecule/aptamer competition assays

15 Small molecule oligoanions were screened for their ability to compete with PDGF
aptamer 20tb for binding to the PDGF-BB protein. The small molecule (or cold 20tb)
competitors at varying concentrations were mixed with the 5'-³²P end-labeled 20tb ligand
at room temperature. PDGF was then added to the mixture and allowed to equilibrate for
20 45 minutes at room temperature followed by 15 minutes at 37°C. The competition
mixtures (90 μL volume) all had ³²P end-labeled 20tb at 1.16 nM, PDGF-BB at 1 nM and
were in 25 mM Hepes, 137 mM NaCl, 2.7 mM KCl, 1mM MgCl₂, 1 mM CaCl₂, 0.067%
human serum albumin (HSA), at pH 7.4 (HBSMC). Aptamer bound to PDGF was
separated from free aptamer by filtration through pre-washed 0.45 μM nitrocellulose
25 membrane filters (Millipore; Bedford, MA). Filters were washed with 5 mL HBSMC at
room temperature. The filters were placed in tubes with scintillant and the radioactivity
counted to quantitate the fraction of ³²P end-labeled 20tb bound at each competitor
concentration.

Small molecule oligosaccharides were screened for their ability to compete with
30 WGA aptamer 11.20 for binding to wheat germ agglutinin protein. The small molecule
(or cold 11.20) competitors at varying concentrations were mixed with the 5'-³²P end-
labeled 11.20 ligand at room temperature. Then WGA was added to the mixture and
allowed to equilibrate for 60 minutes at room temperature. The competition mixtures (90

μL volume) all had ³²P end-labeled 11.20 at 10 nM, WGA at 10 nM and were in 25 mM Hepes, 137 mM NaCl, 2.7 mM KCl, 1mM MgCl₂, 1 mM CaCl₂, 0.067% human serum albumin (HSA), at pH 7.4 (HBSMC). Aptamer bound to WGA was separated from free aptamer by filtration through pre-washed 0.45 μM nitrocellulose membrane filters. Filters were washed with 5 mL HBSMC at room temperature. The filters were placed in tubes with scintillant and the radioactivity counted to quantitate the fraction of ³²P end-labeled 11.20 bound at each competitor concentration.

Analysis of competition data

Competition experiments were analyzed using equation (1) to determine the concentration of free protein, [P_F], as a function of the total concentration of competitor added, [C_T]:

$$[P_F] = [P_T] / (1 + K_{dR}[R_T] / (1 + K_{dR}[P_F]) + K_{dC}[C_T] / (1 + K_{dC}[P_F])) \quad (1)$$

where K_{dR} is the binding constant of species R to the protein (assuming 1:1 stoichiometry) and K_{dC} is the binding constant of species C, the competitor, to the protein (assuming 1:1 stoichiometry). Equation (1) was solved to self-consistency of [P_F] to a precision of 1x10⁻¹⁵. Using these values of [P_F], the concentration of protein-ligand complex [PR] as a function of [C_T] was determined using equation (2):

$$[PR] = K_{dR}[R_T][P_F] / (1 + K_{dC}[P_F]) \quad (2)$$

Since the experimental data are expressed as %[PR], the calculated concentration of [PR] was normalized by [PR₀], the [PR] in the absence of the competitor. [PR₀] was obtained by solving equation (1) where [C_T] = 0. The maximum (M) and minimum (B) %[PR] were allowed to float during the analysis as shown in equation (3):

$$\%[PR] = [PR] / [PR_0] (M - B) + B \quad (3)$$

A non-linear least-squares fitting procedure was used as described by Bates and Watts (Bates and Watts (1988) in *Non-Linear Regression Analysis and its Applications*, D.M.

Bates and D.G. Watts editors, John Wiley & Sons, NY, NY). The program used was originally written in C program language by Dominic Zichi and Brenda Javornic, NeXstar Pharmaceuticals, Inc. The data were fit to equations (1) to (3) to obtain best fit parameters for K_{dc} , M and B as a function of $[C_T]$ while leaving K_{dr} and $[P_T]$ constant.

5

Inhibition of PDGF stimulated [3H]-thymidine incorporation

A10 rat smooth muscle cells were plated in 96 well tissue culture plates at $7-8 \times 10^3$ per well in 100 μ L DME + 4.5 g/L glucose + HEPES + 0.1% FBS and starved for about 20 hours. Aptamers or small molecule oligoanions were titrated across the 96 well plate in triplicate wells from 1 mM to 0.3 μ M by 1:3 dilution steps for the oligoanions and from 1 μ M to 0.3 nM by 1:3 steps for the aptamers. Immediately, PDGF-BB was added to 10 ng/mL to all wells except the unstimulated controls. Positive controls had only PDGF-BB, no other compounds. After 6 hours at 37°C in 5% CO₂, 3H -thymidine was added (0.25 μ Ci per well) and incubated for another 24 hours. Cells were lysed in 1% triton-X 100 for 20-30 minutes on a slow shaker at room temperature, then harvested onto 96 well glass fiber filter plates (Packard) and dried. Scintillant was added and incorporated 3H -thymidine radioactivity counted. EC50 values for inhibition of PDGF-BB-induced 3H -thymidine uptake were obtained by fitting the data to the nonlinear regression with variable slope model of the GraphPad Prism computer program (GraphPad Software).

20

Example 2. PDGF aptamer competition assay

For the PDGF competition assay, a DNA PDGF aptamer sequence identified previously was used. The aptamer and methods used herein are described in detail in Example One. Aptamers obtained in this experiment bind preferentially to the B-chain of PDGF in a manner that inhibits receptor binding and PDGF-BB-induced DNA synthesis *in vitro*. Using photo-crosslinking experiments, it has been shown that a specific nucleotide in the aptamer interacts with phenylalanine-84 of the PDGF B-chain which is located near the region of PDGF known to be involved in receptor binding (Green *et al.* (1996) Biochemistry 35:14413-24). To facilitate detection of competitors in the micromolar range, the affinity of the PDGF aptamer 20ta ($K_d=50$ pM), a 33-mer, was deliberately reduced about 10-fold by additional truncations. The aptamer used for competition binding experiments, 20tb, is a 27-mer that binds to PDGF-BB with a K_d of 0.5 nM.

30

A panel of oligoanions, mostly in the naphthalene sulfonic acid class, were screened for their ability to displace a ^{32}P -radiolabeled aptamer (20tb) from PDGF-BB. These compounds were chosen because suramin and several other members of this family inhibit the binding of PDGF to cells that express the PDGF receptor (Garrett *et al.* (1984) PNAS 81:7466-7470; Powis *et al.* (1992) Cancer Chemother. Pharmacol. 31:223-228). Since the PDGF aptamer also inhibits receptor binding (and with considerably greater potency), it was reasonable to expect that suramin and the aptamer bind to PDGF in a mutually exclusive manner. This was a deliberately biased library and was not intended to approximate any conventional or combinatorial libraries but simply to demonstrate that such competition assays are feasible. A nitrocellulose filter binding method was used to separate bound from unbound aptamer. Structures of competitors used in this competition assay are shown in Figure 1 along with the K_{dc} values calculated from the competition profiles (Figure 2) according to equations (1)-(3) (Experimental Methods). For all competition experiments, the concentration of the ^{32}P end-labeled 20tb aptamer and PDGF-BB was 1.16 nM and 1.0 nM, respectively. Binding reactions were done at 37°C and the time of incubations was at least 60 minutes to insure that the equilibrium was established ($t_{1/2}$ of dissociation for the aptamer from PDGF-BB is about 2 min.). Fast dissociation kinetics are clearly advantageous in these assays since they reduce the length of time required to reach equilibrium.

Among the eleven compounds in the naphthalene sulfonic acid derivatives class, there is clearly a range of affinities for PDGF. Suramin, a hexaanion, is actually not the best ligand for PDGF-BB. Inspection of this set clearly suggests that the placement of the sulfonic acid groups (or anions in general) in space is a strong determinant of binding affinity. For example, naphthalene 1,3,6-trisulfonic acid binds with a K_{dc} of 870 μM whereas SPADNS (another trianion with certain structural similarity to naphthalene 1,3,6-trisulfonic acid) binds with a K_{dc} of 19 μM . The total number of negative charges seems to be less important than their appropriate placement (compare suramin, a hexaanion with *myo*inositol hexasulfate, also a hexaanion or sucrose octasulfate, an octaanion).

Example 3. Effect of ligands on PDGF-induced ³T-thymidine synthesis in A10 rat smooth muscle cells

The same panel of small molecule oligoanions was tested for its effect on PDGF-
5 BB-induced ³T-thymidine incorporation in A10 rat smooth muscle cells as described in
Example 1. The EC50 values for all compounds tested were calculated as described in
Example 1 and are listed in Figure 1.

Example 4. Wheat Germ Agglutinin aptamer competition assay

10

For the WGA competition assay, a 2'-aminopyrimidine RNA aptamer 11.20
identified previously was used. The aptamer and methods used herein are described in
detail in Example 1. Aptamer 11.20 was selected by incubating a randomized nucleic acid
library with WGA, removing the unbound molecules and then displacing the aptamers
15 bound to a specific site with a competitor, (GlcNAc)₃. Thus, unlike the PDGF aptamer,
which was selected for high affinity binding anywhere on the protein, the WGA aptamers
were selected for binding to a specific site, the (GlcNAc)₃ binding site. Aptamer 11.20
and related aptamers isolated by this procedure potently inhibited WGA-mediated
agglutination of sheep erythrocytes. Not surprisingly, aptamer 11.20 and related aptamers
20 could be displaced with (GlcNAc)₃ (as described in United States Patent No. 5,780,228,
entitled, "High Affinity Nucleic Acid Ligands to Lectins," issued July 14, 1998).

A group of carbohydrates related to GlcNAc₃ were tested for their ability to
displace radiolabeled aptamer 11.20 from WGA. As with PDGF, nitrocellulose filter
binding assay was used to separate bound from unbound aptamer. Structures of
25 competitors used in this assay are shown in Figure 3 along with the K_{dc} values calculated
from the competition profiles (Figure 4) according to equations (1)-(3). Binding
conditions are described in detail in Example 1.

Among the carbohydrates tested there is a wide range of affinities for WGA. The
best ligands were (GlcNAc)₄, (GlcNAc)₃, and (GlcNAc)₂, in that order (Figures 3 and 4).
30 This result is in agreement with previous observations (Goldstein and Poretz (1986) in:
The Lectins. Properties, Functions, and Applications in Biology and Medicine, Academic
Press, NY, pp 233-247.). GlcNAc was not a competitor in this concentration range. The
ability of (GlcNAc)₃ and GlcNAc to inhibit WGA-mediated agglutination was tested
previously (see United States Patent No. 5,780,228, entitled "High Affinity Nucleic Acid

Ligands to Lectins," issued July 14, 1998) (18.5 μ M and 800 μ M of the two compounds, respectively, were required to completely inhibit agglutination). Thus, for a subset of carbohydrates tested in the competition assay, K_{dc} values correlate with inhibitory potency in a functional assay.

What is claimed is:

1. A method for determining whether a non-nucleic acid molecule binds to a target comprising displacing a nucleic acid ligand having an affinity for said target with
5 said non-nucleic acid molecule.
2. A method for determining whether a non-nucleic acid molecule binds to a target comprising:
 - a) immobilizing a target to a solid support;
 - 10 b) contacting a labeled nucleic acid ligand with said target wherein binding of the nucleic acid ligand to the target occurs to form a complex;
 - c) adding a non-nucleic acid molecule to the complex wherein a non-nucleic acid molecule that competes with the nucleic acid ligand for binding to the target will disrupt the complex and liberate the nucleic acid ligand; and
 - 15 d) detecting the liberated nucleic acid ligand thereby determining that said non-nucleic acid molecule binds to said target.
3. The method of claim 2 wherein said nucleic acid ligand is identified by the method comprising:
 - 20 i) preparing a candidate mixture of nucleic acids;
 - ii) contacting the candidate mixture of nucleic acids with said target, wherein nucleic acids having an increased affinity to said target relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
 - iii) partitioning the increased affinity nucleic acids from the remainder
25 of the candidate mixture; and
 - iv) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to said target, whereby a nucleic acid ligand may be identified.
4. The method of claim 2 wherein said label is selected from the group
30 consisting of radio activity, fluorescence, chemiluminescence.

5. The method of claim 2 wherein said non-nucleic acid molecule is a small molecule.

6. A method for determining whether a non-nucleic acid molecule binds to a target comprising:

- a) immobilizing a nucleic acid ligand to a solid support;
- b) contacting a labeled target with said nucleic acid ligand wherein binding of the nucleic acid ligand to the target occurs to form a complex;
- c) adding a non-nucleic acid molecule to the complex wherein a non-nucleic acid molecule that competes with the nucleic acid ligand for binding to the target will disrupt the complex and liberate the target; and
- d) detecting the liberated target thereby determining that said non-nucleic acid molecule binds to said target.

7. The method of claim 6 wherein said nucleic acid ligand is identified by the method comprising:

- i) preparing a candidate mixture of nucleic acids;
- ii) contacting the candidate mixture of nucleic acids with said target, wherein nucleic acids having an increased affinity to said target relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
- iii) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and
- iv) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to said target, whereby a nucleic acid ligand may be identified.

8. The method of claim 6 wherein said label is selected from the group consisting of radio activity, fluorescence, chemiluminescence.

9. The method of claim 6 wherein said non-nucleic acid molecule is a small molecule.

1/10







| <u>Competitor</u> | <u>Structure</u> | <u>K_{dc}, μM</u> | <u>EC₅₀, μM</u> |
|-------------------|---|---------------------------|----------------------------|
| Evans Blue |  | 0.15 ± 0.04 | 5.6 |
| Trypan Blue |  | 0.26 ± 0.06 | 6.1 |
| Suramin |  | 1.1 ± 0.4 | 57 |
| Calcion |  | 7.8 ± 1.2 | 280 |
| SPADNS |  | 19 ± 6 | 100 |
| Azocarmine B |  | 22 ± 3.0 | >1000 |

Figure 1

2/10







| <u>Competitor</u> | <u>Structure</u> | <u>K_{dC}, μM</u> | <u>EC₅₀, μM</u> |
|------------------------------------|--|---------------------------|----------------------------|
| Amaranth |  | 48 ± 16 | 510 |
| Sulfonazo III |  | 74 ± 27 | >1000 |
| New Coccine |  | 120 ± 20 | 930 |
| myoinositol hexasulfate |  | 720 ± 200 | >1000 |
| Naphthalene 1,3,6-trisulfonic acid |  | 870 ± 400 | >1000 |
| Sucrose octasulfate |  | 1740 ± 450 | >1000 |

Figure 1, continued

3/10

| <u>Competitor</u> | <u>Structure</u> | <u>K_d, μM</u> | <u>EC50, μM</u> |
|------------------------|------------------|---|--------------------------------|
| PDGF Aptamer (20ta) | | 0.000050 \pm 0.000055 | |
| PDGF Aptamer (20tb) | | 0.00039 \pm 0.00016 | |
| PDGF Aptamer(PD 316) | | 0.000070 \pm 0.000030 | 0.005 |
| VEGF Aptamer (31838SP) | | >1 | >1 |

Figure 1, continued




FIGURE 2A




FIGURE 2B

5/10




FIGURE 2C

| <u>Competitor</u> | <u>Structure</u> | <u>K_{dC}, μM</u> |
|-----------------------|------------------|---------------------------|
| GlcNAc | | >10000 |
| (GlcNAc) ₂ | | 83 ± 21 |
| (GlcNAc) ₃ | | 4 ± 0.3 |
| (GlcNAc) ₄ | | 1.3 ± 0.3 |
| Fuc1-α-4GlcNAc | | 8100 ± 5200 |
| Fuc1-α-3GlcNAc | | 6600 ± 5300 |

Figure 3

7/10






| <u>Competitor</u> | <u>Structure</u> | <u>K_{DC}, μM</u> |
|---|--|---------------------------|
| Lewis A trisaccharide {Gal1-B-3[Fuc1-α-4] GlcNAc} |  | 1500 ± 400 |
| Lewis X trisaccharide {Gal1-B-4[Fuc1-α-3] GlcNAc} |  | 2600 ± 1400 |
| Lewis Y tetrasaccharide {Fuc1-α-2Gal1-B-4 [Fuc1-α-3]GlcNAc} |  | 5400 ± 7000 |
| Sialyl Lewis A |  | 6100 ± 1000 |
| Sialyl Lewis X |  | 2800 ± 300 |

Figure 3, continued




| <u>Competitor</u> | <u>Structure</u> | <u>K_{dC}, mM</u> |
|----------------------------|--|---------------------------|
| LacNAc {Gal1-B-4GlcNAc} |  | 480 ± 250 |
| Sialyl-a-3LacNAc |  | 540 ± 170 |
| Sialyl-B-3LacNAc |  | 440 ± 200 |

Figure 3, continued




FIGURE 4A




FIGURE 4B




FIGURE 4C




FIGURE 4D

SEQUENCE LISTING

<110> NeXstar Pharmaceuticals, Inc.

<120> Aptamers as Reagents for high Throughput Screening

<130> NEX 78/PCT

<140>

<141>

<150> 09/246,461

<151> 1999-02-09

<160> 4

<170> PatentIn Ver. 2.0

<210> 1

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic acid
ligand

<400> 1

cgggcgcggtt cttcgtggtt acttttagtc ccg 33

<210> 2

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic acid
ligand

<400> 2

gggccggttc gggttacttt tagtccc 27

<210> 3

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic acid
ligand

<220>

<221> modified_base

<222> (1)..(31)

<223> The t at position 1 is 2'-NH₂. The u's and c's at
positions 7, 9, 20, 21, 27, 28 and 29 are 2'-F.
The a's and g's at positions 10, 15, 17, 22 and 30
are 2'-O-methyl.

<220>

<221> modified_base

<222> (1)..(31)

<223> The g at position 10 and the a at position 22 have
been modified with polyethylene glycol of 18
units.

<400> 3

tcaggcuacg cgtagagcau catgatccug t

31

<210> 4

<211> 97

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic acid
ligand

<220>

<221> modified_base

<222> (1)..(97)

<223> All u's and c's are 2'-aminopyrimidines

<400> 4

gggaaaagcg aaucauacac aagauugguc guacuggaca gagccguggu agagggauug 60
ggacaaagug ucagcuccgc cagagaccaa ccgagaa 97

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/02490

| A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12Q 1/68; C07K 1/00, 17/00; C07H 21/00 US CL : 435/6; 530/402, 413, 810, 812; 536/23.1 According to International Patent Classification (IPC) or to both national classification and IPC | | | | | | | | | | | | | | |
|---|--|--|--|--|--|--|--|--|---|---|--|--|--|--|
| B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6; 530/402, 413, 810, 812; 536/23.1 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WEST (U.S. PATENTS) search terms: competitive, binding, displacing, nucleic acid, ligand, target, support | | | | | | | | | | | | | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | | | | | | | | | | | | | |
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. | | | | | | | | | | | | |
| X ---- Y | US 5,780,228 A (PARMA et al.) 14 July 1998, entire document, especially paragraph bridging columns 18 and 19. | 1 ---- 2-9 | | | | | | | | | | | | |
| X ---- Y | US 5,580,737 A (POLISKY et al.) 03 December 1996, entire document, especially column 17, lines 49-62, and column 18, lines 48-60. | 1 ---- 2-9 | | | | | | | | | | | | |
| Y | US 5,789,163 A (DROLET et al.) 04 August 1998, entire document, especially column 4, lines 19-37, column 3, lines 44-46, and column 15, lines 57-58. | 2-9 | | | | | | | | | | | | |
| <input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex. | | | | | | | | | | | | | | |
| <table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*B* earlier document published on or after the international filing date</td> <td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*G* document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table> | | | * Special categories of cited documents: | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention | *A* document defining the general state of the art which is not considered to be of particular relevance | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone | *B* earlier document published on or after the international filing date | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art | *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *G* document member of the same patent family | *O* document referring to an oral disclosure, use, exhibition or other means | | *P* document published prior to the international filing date but later than the priority date claimed | |
| * Special categories of cited documents: | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention | | | | | | | | | | | | | |
| *A* document defining the general state of the art which is not considered to be of particular relevance | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone | | | | | | | | | | | | | |
| *B* earlier document published on or after the international filing date | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art | | | | | | | | | | | | | |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *G* document member of the same patent family | | | | | | | | | | | | | |
| *O* document referring to an oral disclosure, use, exhibition or other means | | | | | | | | | | | | | | |
| *P* document published prior to the international filing date but later than the priority date claimed | | | | | | | | | | | | | | |
| Date of the actual completion of the international search 18 MAY 2000 | | Date of mailing of the international search report 20 JUN 2000 | | | | | | | | | | | | |
| Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 | | Authorized officer DAVID M. NAFF Telephone No. (703) 308-0196 JOYCE BRIDGERS PARALEGAL SPECIALIST CHEMICAL MATRIX | | | | | | | | | | | | |